FURTHER INFORMATION ABOUT OUR COMPANY AND OUR SUBSIDIARIES

Incorporation

Our Company was established as a limited liability company in the PRC on January 5, 2016 and was converted into a joint stock limited company on July 18, 2025 under the laws of the PRC. As of the Latest Practicable Date, the total share capital of the Company was RMB53,999,444 comprising 53,999,444 Shares of nominal value RMB1.00 each. Immediately upon [**REDACTED**], the ordinary Shares of the Company will be subdivided on a one-for-ten basis, and the nominal value of the Shares will be changed from RMB1.0 each to RMB0.1 each. Immediately after the Share Subdivision, the registered share capital of the Company was RMB53,999,444 divided into 539,994,440 Shares of nominal value RMB0.1 each.

Our principal place of business in Hong Kong is at Unit B, 9/F, Pangkin Centre, 332-334 Portland Street, Mong Kok, Hong Kong. Our Company has been registered as a non-Hong Kong company under Part 16 of the Companies Ordinance with the Registrar of Companies in Hong Kong on November 8, 2024 under the name of 四川好醫生雲醫療科技集團有限公司, and was renamed as Good Doctor Cloud Healthcare & Technology Group Co., Ltd. (四川好醫生雲醫療科技集團股份有限公司) on September 22, 2025. Mr. CHOW KIN SHING THOMAS (周健勝) has been appointed as the authorized representative of our Company for the acceptance of service of process in Hong Kong whose address for service of process is Unit B, 9/F, Pangkin Centre, 332-334 Portland Street, Mong Kok, Hong Kong.

As the Company was incorporated in the PRC, its operations are subject to the relevant laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations of the PRC and the Articles of Association is set out in the section headed "Regulatory Overview" and Appendix V, respectively.

Changes in Share Capital

On January 5, 2016, our Company was incorporated with a registered capital of RMB10 million.

Pursuant to a capital increase agreement dated September 30, 2024, Chengdu Jiayue Yingchuang Enterprise Management Consulting Partnership (Limited Partnership) (成都佳越贏創企業管理諮詢合夥企業(有限合夥)) subscribed for an increased share capital of RMB500,000 at a consideration of RMB20,000,000. As a result, our total share capital was increased to RMB50,500,000 on October 28, 2024.

In July 2025, Hangzhou Trizen Medical Technology Co., Ltd. (杭州全診醫學科技有限公司) entered into an capital increase agreement with our Company and our then existing Shareholders to subscribe for 375,000 Shares. As a result, our registered capital was increased from RMB50,500,000 to RMB50,875,000.

In September 2025, Beijing Desai Innovation Equity Investment Center (Limited Partnership) (北京德賽創新股權投資中心(有限合夥)), Shanghai North High Tech Venture Capital Partnership Enterprise (Limited Partnership) (上海市北高新創業投資合夥企業(有限合夥)), Hainan Xichen Kechuang Investment Co., Ltd. (海南希晨科創投資有限公司), Chengdu Sanyi Science and Technology Innovation Equity Investment Fund Partnership (Limited Partnership) (成都三醫科創股權投資基金合夥企業(有限合夥)), Chengdu Rongke Investment Precision Medical Equity Investment Fund Partnership (Limited Partnership) (成都蓉科投精準醫學股權投資基金合夥企業(有限合夥)), Yangzhou Rongke Huizhi Venture Capital Partnership (Limited Partnership) (揚州蓉科匯智創業投資合夥企業(有限合夥)), Chengdu Fengqi Wutong

Venture Capital Fund Partnership (Limited Partnership) (成都鳳棲梧桐創業投資基金合夥企業(有限合夥)), Chengdu Wutong Juhao Enterprise Management Partnership (Limited Partnership) (成都梧桐聚好企業管理合夥企業(有限合夥)), Chengdu Tianfu Jiaozi Sibaiyi Equity Investment Fund Partnership (Limited Partnership) (成都天府交子思佰益股權投資基金合夥企業(有限合夥)), Chengdu Tonglu Enterprise Management Consulting Partnership (Limited Partnership) (成都潼淥企業管理諮詢合夥企業(有限合夥)) and Chengdu Hengzhiyi Enterprise Management Center (Limited Partnership) (成都恒之熠企業管理中心(有限合夥)) subscribed for an aggregate of 3,124,444 Shares of our Company at a total consideration of RMB124,977,778. As a result, our total share capital was increased to RMB53,999,444.

See "History, Development and Corporate Structure — Major Shareholding Changes of Our Group".

Save as disclosed above, there has been no alteration in the share capital of the Company within two years immediately preceding the date of this document.

Resolutions of our Shareholders

At the general meeting of the Shareholders held on September 28, 2025, the following resolutions, among other things, were duly passed:

(a) the sub-division of the Shares with nominal value of RMB1.0 each on the basis of 1:10, effective immediately prior to the [**REDACTED**], and taking into account the Share Subdivision, the issue of H Shares of nominal value of RMB0.1 each and such H Shares be [**REDACTED**] on the Stock Exchange;

(b) the number of H shares to be issued shall be no more than [**REDACTED**]% of the total issued share capital of our Company as enlarged by the [**REDACTED**] before the exercise of the [**REDACTED**], and the grant to the [**REDACTED**] (or their representatives) of the [**REDACTED**] of not more than [**REDACTED**]% of the number of H Shares issued pursuant to the [**REDACTED**];

(c) subject to the filing with CSRC is completed, upon completion of the [**REDACTED**], 539,994,440 [**REDACTED**] Shares taking into account the Share Subdivision will be converted into H Shares on a one-for-one basis;

(d) authorization of the Board or its authorized individual to handle all matters relating to, among other things, the [**REDACTED**], the issue and the [**REDACTED**] of H Shares on the Hong Kong Stock Exchange; and

(e) subject to the completion of the [**REDACTED**], the conditional adoption of the revised Articles of Association, which shall become effective on the [**REDACTED**].

Changes in the Share Capital of our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in Note 1 to the Accountants' Report of the Group as set out in Appendix I to this document.

On November 4, 2024, Tianjin Cloud Healthcare was incorporated as a company with limited liability under the PRC laws, with a registered capital of RMB20 million.

On April 7, 2025, Good Doctor Jiayuetang was incorporated as a company with limited liability under the PRC laws, with a registered capital of RMB2 million.

On December 2, 2025, Chengdu XJND was incorporated as a company with limited liability under the PRC laws, with a registered capital of RMB60 million.

Save as disclosed above, there has been no alteration in the share capital of the subsidiaries of the Company within two years immediately preceding the date of this document.

FURTHER INFORMATION ABOUT OUR BUSINESS

Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by members of our Group within the two years preceding the date of this document and are or may be material:

(a) the capital increase agreement dated July 30, 2025 entered into among Sichuan Good Doctor Cloud Healthcare Technology Group Co. Ltd. (四川好醫生雲醫療科技集團有限公司) (currently known as Good Doctor Cloud Healthcare & Technology Group Co., Ltd. (四川好醫生雲醫療科技集團股份有限公司), the "**Company**"), Hangzhou Trizen Medical Technology Co., Ltd. (杭州全診醫學科技有限公司) ("**Trizen Medical**"), Sichuan Jianengda Investment Co., Ltd. (四川佳能達投資有限公司) ("**Sichuan JND**"), Zhuhai Hengqin JND Cloud Healthcare Investment Partnership Enterprise (Limited Partnership) (珠海橫琴佳能達雲醫療投資合夥企業(有限合夥)) ("**Hengqin Cloud Healthcare**"), CLOUD HEALTH TECHNOLOGY (HK) COMPANY LIMITED (雲醫療科技(香港)有限公司) ("**Cloud Health HK**"), OAP IV (HK) Limited (奧博亞洲四期(香港)有限公司) ("**OAP IV**"), Zhuhai Hengqin JND National Medical Investment Partnership Enterprise (Limited Partnership) (珠海橫琴佳能達國醫投資合夥企業(有限合夥)) ("**Hengqin National Medical Investment**"), Shanghai Kangrang Enterprise Management Partnership (Limited Partnership) (上海康穰企業管理合夥企業(有限合夥)) ("**Shanghai Kangrang**") and Chengdu Jiayue Yingchuang Enterprise Management Consulting Partnership (Limited Partnership) (成都佳越贏創企業管理諮詢合夥企業(有限合夥)) ("**Chengdu Jiayue**"), pursuant to which Trizen Medical agreed to subscribe for 375,000 Shares by contributing its 80% equity interest in Hangzhou Diagnosis Chain Technology Co., Ltd. (杭州診鏈科技有限公司) (renamed as Hangzhou Good Doctor Trizen Medical Technology Co., Ltd. (杭州好醫生全診醫學科技有限公司) in November 2025) ("**Hangzhou Good Doctor Trizen**");

(b) the capital increase and share transfer agreement dated September 22, 2025 entered into among the Company, Beijing Desai Innovation Equity Investment Center (Limited Partnership) (北京德賽創新股權投資中心(有限合夥)) ("**Desai Innovation**"), Shanghai North High Tech Venture Capital Partnership Enterprise (Limited Partnership) (上海市北高新創業投資合夥企業(有限合夥)) ("**North High Tech**"), Hainan Xichen Kechuang Investment Co., Ltd. (海南希晨科創投資有限公司) ("**Hainan Xichen**"), Chengdu Sanyi Science and Technology Innovation Equity Investment Fund Partnership (Limited Partnership) (成都三醫科創股權投資基金合夥企業(有限合夥)) ("**Chengdu Sanyi**"), Chengdu Rongke Investment Precision Medical Equity Investment Fund Partnership (Limited Partnership) (成都蓉科投精準醫學股權投資基金合夥企業(有限合夥)) ("**Chengdu Rongke**"), Yangzhou Rongke Huizhi Venture Capital Partnership (Limited Partnership) (揚州蓉科匯智創業投資合夥企業(有限合夥)) ("**Yangzhou Rongke**"), Chengdu Fengqi Wutong Venture Capital Fund Partnership (Limited Partnership) (成都鳳棲梧桐創業投資基金合夥企業(有限合夥)) ("**Chengdu Fengqi**"), Chengdu Wutong Juhao Enterprise Management Partnership (Limited Partnership) (成都梧桐聚好企業管理合夥企業

(有限合夥)) ("**Chengdu Wutong**"), Chengdu Tianfu Jiaozi Sibaiyi Equity Investment Fund Partnership (Limited Partnership) (成都天府交子思佰益股權投資基金合夥企業(有限合夥)) ("**Tianfu Jiaozi**"), Chengdu Tonglu Enterprise Management Consulting Partnership (Limited Partnership) (成都潼淥企業管理諮詢合夥企業(有限合夥)) ("**Chengdu Tonglu**"), Chengdu Hengzhiyi Enterprise Management Center (Limited Partnership) (成都恒之熠企業管理中心(有限合夥)) ("**Chengdu Hengzhiyi**"), Sichuan JND, Hengqin Cloud Healthcare, Cloud Health HK, OAP IV, Hengqin National Medical Investment, Shanghai Kangrang, Chengdu Jiayue and Trizen Medical, pursuant to which (i) Desai Innovation agreed to subscribe for an increased registered capital of RMB555,556 in our Company with a consideration of RMB22,222,222.22 and agreed to acquire the registered capital of RMB825,163 in our Company from Sichuan JND with a consideration of RMB27,777,777.78; (ii) North High Tech agreed to subscribe for an increased registered capital of RMB555,556 in our Company with a consideration of RMB22,222,222.22 and agreed to acquire the registered capital of RMB825,163 in our Company from Sichuan JND with a consideration of RMB27,777,777.78; (iii) Hainan Xichen agreed to subscribe for an increased registered capital of RMB444,444 in our Company with a consideration of RMB17,777,777.78 and agreed to acquire the registered capital of RMB660,131 in our Company from Sichuan JND with a consideration of RMB22,222,222.22; (iv) Chengdu Sanyi agreed to subscribe for an increased registered capital of RMB666,667 in our Company with a consideration of RMB26,666,666.67 and agreed to acquire the registered capital of RMB990,196 in our Company from Sichuan JND with a consideration of RMB33,333,333.33; (v) Chengdu Rongke agreed to subscribe for an increased registered capital of RMB407,333 in our Company with a consideration of RMB16,293,333.33 and agreed to acquire the registered capital of RMB605,010 in our Company from Sichuan JND with a consideration of RMB20,366,666.67; (vi) Yangzhou Rongke agreed to subscribe for an increased registered capital of RMB37,111 in our Company with a consideration of RMB1,484,444.44 and agreed to acquire the registered capital of RMB55,121 in our Company from Sichuan JND with a consideration of RMB1,855,555.56; (vii) Chengdu Fengqi agreed to subscribe for an increased registered capital of RMB111,111 in our Company with a consideration of RMB4,444,444.44 and agreed to acquire the registered capital of RMB165,033 in our Company from Sichuan JND with a consideration of RMB5,555,555.56; (viii) Chengdu Wutong agreed to subscribe for an increased registered capital of RMB11,111 in our Company with a consideration of RMB444,444.44 and agreed to acquire the registered capital of RMB16,503 in our Company from Sichuan JND with a consideration of RMB555,555.56; (ix) Tianfu Jiaozi agreed to subscribe for an increased registered capital of RMB222,222 in our Company with a consideration of RMB8,888,888.89 and agreed to acquire the registered capital of RMB330,065 in our Company from Sichuan JND with a consideration of RMB11,111,111.11; (x) Chengdu Tonglu agreed to subscribe for an increased registered capital of RMB2,222 in our Company with a consideration of RMB88,888.89 and agreed to acquire the registered capital of RMB3,301 in our Company from Sichuan JND with a consideration of RMB111,111.11; (xi) Chengdu Hengzhiyi agreed to subscribe for an increased registered capital of RMB111,111 in our Company with a consideration of RMB4,444,444.44 and agreed to acquire the registered capital of RMB165,033 in our Company from Sichuan JND with a consideration of RMB5,555,555.56; and (xii) OAP IV agreed to acquire the registered capital of RMB2,597,143 in our Company from Cloud Health HK with a consideration of RMB72,000,000.00; and

(c) [**REDACTED**].

Intellectual Property Rights

Trademarks

(a) Registered Trademarks

As at the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of registration	Rights holder	Class	Registration number	Expiration Date (yyyy-mm-dd)
1	好醫生雲醫療 GOOD DOCTOR CLOUD HEALTHCARE	Hong Kong	Our Company	5, 9, 10, 16, 35, 41, 42, 44	306709780	2034-10-29
2		Hong Kong	Our Company	5, 9, 10, 16, 35, 41, 42, 44	306709753	2034-10-29
3	好医生云医疗 GOOD DOCTOR CLOUD HEALTHCARE	Hong Kong	Our Company	5, 9, 10, 16, 35, 41, 42, 44	306709762	2034-10-29
4	好醫生雲醫療 GOOD DOCTOR CLOUD HEALTHCARE	Hong Kong	Our Company	5, 9, 10, 16, 35, 41, 42, 44	306709735	2034-10-29
5	好医生云医疗 GOOD DOCTOR CLOUD HEALTHCARE	Hong Kong	Our Company	5, 9, 10, 16, 35, 41, 42, 44	306709717	2034-10-29
6	健贝儿	PRC	Our Company	5	81624754	2035-04-27
7	古方悬壶	PRC	Our Company	30	78903315	2034-12-06
8	佳越堂 大药房	PRC	Our Company	35	78411206	2034-11-06
9	佳越堂	PRC	Our Company	35	78414269	2034-11-06
10 . . .	健贝儿	PRC	Our Company	5	3715591	2036-02-13
11 . . .	诊宝倍	PRC	Our Company	10	75579685	2034-06-13
12 . . .	小葫芦宝	PRC	Our Company	5	73660476	2034-06-06
13 . . .	药约约	PRC	Our Company	9	62502324	2033-07-06
14 . . .	小葫芦宝	PRC	Our Company	5	45466175	2031-02-27
15 . . .	小葫芦宝	PRC	Our Company	5	45456210	2031-02-27

THIS DOCUMENT IS IN DRAFT FORM. THE INFORMATION CONTAINED HEREIN IS INCOMPLETE AND IS SUBJECT TO CHANGE. THIS DOCUMENT MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED "WARNING" ON THE COVER OF THIS DOCUMENT.

No.	Trademark	Place of registration	Rights holder	Class	Registration number	Expiration Date (yyyy-mm-dd)
16 . . .	古方悬壶	PRC	Our Company	5	36055845	2029-09-13
17 . . .		PRC	Our Company	44	20815630	2027-09-20

(b) Licensed Trademarks

As of the Latest Practicable Date, we were licensed to use the following registered trademarks which we consider to be or may be material to our business:

No.	Trademark	Rights holder	Place of registration
1 . . .	好医生*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
2	*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
3	*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
4	维全佳*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
5	松克*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
6	数九*	Sichuan JND	PRC
7	蜀汉本草*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
8	赛奥*	四川好醫生攀西藥業有限責任公司	PRC
9	轻克*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
10 . . .	快捷克*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
11 . . .	快捷克*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
12 . . .	壳壳保*	Sichuan JND	PRC
13 . . .	康复馨*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
14 . . .	好医生好妈妈*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
15 . . .	*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
16 . . .	好健膳*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
17 . . .	好伙伴*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
18 . . .	好大夫*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
19 . . .	豪克*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC

No.	Trademark	Rights holder	Place of registration
20 . . .	福柔*	Sichuan Funengyuan Biological Technology Co., Ltd.(四川福能源生物科技有限公司)	PRC
21 . . .	芙新*	Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd. (四川好醫生攀西藥業有限責任公司)	PRC
22 . . .	夫可宁*	Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd. (四川好醫生攀西藥業有限責任公司)	PRC
23 . . .	多维金档*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
24 . . .	驰铭*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC
25 . . .	CHMOUS*	Good Doctor Pharmaceutical Group Co., Ltd. (好醫生藥業集團有限公司)	PRC

Note:

* denotes the Licensed Trademarks licensed to us by Sichuan JND and/or its associates under the Trademark Licensing Framework Agreement. For details, please refer to the section headed "Connected Transactions — Fully Exempt Continuing Connected Transaction — 1. Trademark Licensing".

Patents

As at the Latest Practicable Date, we had registered the following patents which we consider to be or may be material to our business:

No.	Patent Name	Category	Patentee	Place of registration	Patent number	Grant date (yyyy-mm-dd)
1 . .	System and Artificial Intelligence Method for Determining Medical Labels Based on Laboratory Test Results (基於檢驗結果確定醫學標籤的系統及人工智能方法)	Invention Patent	Our Company	PRC	ZL201911136284.6	2023-08-01
2 . .	Sales Control Management Method, Platform, and System Based on Sales Control Cycle (基於控銷週期的控銷管理方法、控銷管理平台及系統)	Invention Patent	Our Company	PRC	ZL202111273128.1	2024-09-24
3 . .	A process engine framework design method based on WF4.5 (一種基於WF4.5的流程引擎框架設計方法)	Invention Patent	Good Doctor Medical Laboratory	PRC	CN201710708090.3	2020-11-10

Copyrights

As at the Latest Practicable Date, we had registered the following copyrights which we consider to be or may be material to our business:

No.	Copyright	Place of Registration	Copyright Owner	Registration Number	Registration Date (yyyy-mm-dd)
1 . . .	Yao Yue Yue Pharmaceutical Management Terminal Software (藥約約管理端軟件)	PRC	Our Company	2024SR1029443	2025-09-22
2 . . .	Zhen Jiao Shou Medical Service Terminal Software (診教授業務端軟件)	PRC	Our Company	2024SR1029455	2025-09-22
3 . . .	Zhen Bao Bei Laboratory Department Software (診寶倍檢驗科軟件)	PRC	Our Company	2024SR0886536	2025-09-22
4 . . .	Cloud Inspection Smart Order System (雲檢驗智能下單系統)	PRC	Our Company	2024SR0765696	2025-09-22
5 . . .	Good Doctor Cloud Clinic Blood Testing System (好醫生雲診所血檢系統)	PRC	Our Company	2024SR0745738	2025-09-22
6 . . .	Cloud ECG Reading Terminal System (雲檢驗心電閱片端系統)	PRC	Our Company	2024SR0738414	2025-09-22
7 . . .	Hao Yao You Xuan Pharmaceutical E-commerce Management Terminal Software (好藥優選管理端軟件)	PRC	Our Company	2024SR0687103	2025-09-22
8 . . .	Brand Sales Control Selection Software (品牌控銷甄選軟件)	PRC	Our Company	2024SR0687100	2025-09-22
9 . . .	Cloud Medical Permission Management System (雲醫療權限管理系統)	PRC	Our Company	2023SR1408178	2023-11-09
10 . .	Zhen Bao Bei (診寶貝)	PRC	Our Company	2024SR0752316	2025-09-22
11 . .	Nick Doctor Remote Ambulatory Blood Pressure Monitoring System (尼克醫生遠程動態血壓檢測系統)	PRC	Our Company	2024SR0687110	2025-09-22
12 . .	Haoyisheng Cloud Medical Horte Doctor Imaging Review Terminal (好醫生雲醫療霍特醫生閱片端系統)	PRC	Our Company	2024SR0687107	2025-09-22
13 . .	Yao Yue Yue Pharmaceutical E-commerce System (藥約約醫藥電商系統)	PRC	Sichuan XJND	2023SR0553639	2023-05-19
14 . .	Zhen Jiao Shou Software (診教授軟件)	PRC	Sichuan XJND	2023SR0553638	2023-05-19

No.	Copyright	Place of Registration	Copyright Owner	Registration Number	Registration Date (yyyy-mm-dd)
15 . .	Zhen Bao Bei Software (診寶倍軟件)	PRC	Good Doctor Medical Laboratory	2023SR1159023	2023-09-26
16 . .	Yao Yue Yue Software (藥約約軟件)	PRC	Chongzhou Cloud Healthcare	2024SR1204044	2024-08-19
17 . .	Good Doctor Cloud Medical (好醫生雲醫療)	PRC	Our Company	國作登字-2021-F-00044418	2021-02-24
18 . .	Good Doctor Pharmaceuticals (好醫生藥業)	PRC	Sichuan XJND	2023SR0553641	2023-05-19
19 . .	Yueyaoke Software (約約康軟體)	PRC	Sichuan XJND	2023SR1646016	2023-12-14
20 . .	Good Medicine Preferred Medical E-commerce System V1.0 (好藥優選醫藥電商系統V1.0)	PRC	Sichuan XJND	2023SR0506426	2023-04-27

Domain names

As of the Latest Practicable Date, we owned the following domain names which we consider to be or may be material to our business:

No.	Domain names	Obligee	Expiration date (yyyy-mm-dd)
1	haoyaoyouxuan.com	Sichuan XJND	2027-07-02
2	zhenjiaoshou.com	Sichuan XJND	2027-02-15
3	hysyyl.com	Good Doctor Medical Laboratory	2027-04-20
4	hyshospital.com	Good Doctor Internet Hospital	2029-01-26
5	yaoyueyue.com	Chongzhou Cloud Healthcare	2029-03-12
6 . . .	aihys.com	Hangzhou Good Doctor Trizen	2026-07-04
7 . . .	aihs.org.cn	Hangzhou Good Doctor Trizen	2026-08-11
8 . . .	aioclinic.com	Hangzhou Good Doctor Trizen	2027-04-02

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks, patents, intellectual or industrial property rights which were material in relation to our business.

FURTHER INFORMATION ABOUT OUR DIRECTORS, MANAGEMENT AND SUBSTANTIAL SHAREHOLDERS

Particulars of the Service Contracts

We [have entered] into a contract with each of our Directors in respect of, among other things (i) compliance of relevant laws and regulations, (ii) observance of the Articles of Association, and (iii) provisions on dispute resolution.

Save as disclosed above, none of the Directors has entered into any service contracts as a director with any member of the Group (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)).

Directors' Remuneration

The Directors receive remuneration in the forms of salaries, allowances and benefits in kind, performance related bonuses, share-based payment expenses, and pension scheme contributions.

The aggregate amount of remuneration (including salaries, allowances and benefits in kind, performance related bonuses, share-based payment expenses, and pension scheme contributions) paid to our Directors for the three years ended December 31, 2023, 2024 and 2025 were approximately RMB1.57 million, RMB3.58 million and RMB3.67 million, respectively.

Disclosure of interests

Immediately following completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised), the interests and/or short positions of our Directors and chief executive in our Shares, underlying shares and debentures of our Company and its associated corporations, within the meaning of Part XV of the SFO, which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she is taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules, will be as follows:

(a) Interests in our Company

Name of Director or Chief Executive	Nature of Interest	Number and Description of Shares(1)	Approximate percentage of Shareholding following the completion of the [REDACTED](1)
Ms. Geng Jie(2)(4)	Interest in controlled corporation	114,528,570 H Shares (L)	[REDACTED]%
	Interest held jointly with other persons	356,349,950 H Shares (L)	[REDACTED]%
Mr. Geng Yuefei(2)(4)	Interest in controlled corporation	39,250,000 H Shares (L)	[REDACTED]%
	Interest held jointly with other persons	356,349,950 H Shares (L)	[REDACTED]%
Mr. Xue Yuan(3)(4)	Interest of spouse	114,528,570 H Shares (L)	[REDACTED]%
Mr. Su Yazhou	Interest in controlled incorporation	29,150,000 H Shares (L)	[REDACTED]%

Notes:

(L) All interests are long positions.

(1) The calculation is based on the assumption that (i) the Share Subdivision is completed, (ii) the [**REDACTED**] is not exercised, (iii) the 539,994,440 [**REDACTED**] Shares (taking into account the Share Subdivision) will be converted into H Shares, and (iv) the total number of the Shares in issue will be [**REDACTED**] H Shares immediately after completion of the [**REDACTED**].

(2) Pursuant to the acting-in-concert agreement dated January 1, 2022, Ms. Geng Jie, Mr. Geng Funeng and Mr. Geng Yuefei shall act in concert when exercising their respective right to propose, nominate and vote with respect to all material matters concerning the affairs of the Company. See "Relationship with Controlling Shareholders — Controlling Shareholders Group" and "Substantial Shareholders". Therefore, each of Ms. Geng Jie, Mr. Geng Funeng and Mr. Geng Yuefei is deemed to be interested in the interest of each other under the SFO.

(3) Ms. Geng Jie and Mr. Xue Yuan are spouses, and hence are deemed to be interested in the interest of each other under the SFO.

(4) As at the Latest Practicable Date, Ms. Geng Jie, Mr. Geng Funeng, Mr. Geng Fuchang, Mr. Geng Yuefei, Mr. Xue Yuan, Sichuan JND, Cloud Health HK, Hengqin Cloud Healthcare, Hengqin National Medical Investment and Jiayue Ruihe were collectively entitled to control the exercise of approximately 65.99% of the voting rights at the general meeting of our Company, they constituted as of the Latest Practicable Date and will continue to constitute upon the [**REDACTED**] a group of controlling shareholders of our Company. For further details, please see "Relationship with Controlling Shareholders" and "Substantial Shareholders".

Save as disclosed above, none of the Directors or the chief executive officer of the Company will, immediately following completion of the [**REDACTED**], has any interests and/or short positions in the Shares, underlying Shares and debentures of our Company's associated corporations (within the meaning of Part XV of the SFO), which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she is taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

Substantial Shareholders

(a) Interests in our Company

For information on the persons who will, immediately following the completion of the [**REDACTED**], having or be deemed or taken to have beneficial interests or short position in our Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, see the section headed "Substantial Shareholders" in this document.

(b) Interests of the Substantial Shareholders of Other Members of Our Group

Save as disclosed in this document, our Directors are not aware of any other person who will, immediately following the [**REDACTED**] and the Conversion of [**REDACTED**] Shares into H Shares (and the [**REDACTED**] of any additional H Shares pursuant to the [**REDACTED**]), have an interest or short position in Shares or underlying Shares of the Company, which would be required to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or will, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meeting of the Group.

Pre-[REDACTED] Share Incentive Scheme

The Company has adopted the Pre-[**REDACTED**] Share Incentive Scheme by a resolution of our Shareholders on September 22, 2025. Under the Pre-[**REDACTED**] Share Incentive Scheme, the eligible participants as approved may indirectly hold our Company's interest by holding partnership interest in our employee shareholding platforms, namely, Chaoyue Gongchuang No. 1 and Chaoyue Gongchuang No. 2. As of the Latest Practicable Date, assuming the Share Subdivision is completed, 20,200,000 Shares subject to the

Pre-[**REDACTED**] Share Incentive Scheme were held by the employee shareholding platforms, representing approximately 3.74% of the aggregate amount of the Shares in issue immediately before the completion of the [**REDACTED**]. The general partner of the employee shareholding platforms is entitled to exercise the voting rights in the Company held by the employee shareholding platforms. The Pre-[**REDACTED**] Share Incentive Scheme is not subject to the provisions of Chapter 17 of the Listing Rules as all the award pursuant to the Pre-[**REDACTED**] Share Incentive Scheme have been granted and no new option or awards will be granted by our Company under the Pre-[**REDACTED**] Share Incentive Scheme after the [**REDACTED**].

(a) Purposes

The purpose of the Pre-[**REDACTED**] Share Incentive Scheme is to improve the Company's governance structure, establish an effective incentive and restraint mechanism, enhance the sense of responsibility and mission of core employees for achieving the Company's sustainable and healthy development, and effectively combine the interests of shareholders, the Company and individual employees.

(b) The Number and Price of Shares

A total of 20,200,000 restricted shares, assuming the Share Subdivision is completed, with grant price per restricted share of RMB1.68 were granted under the Pre-[**REDACTED**] Share Incentive Scheme, representing approximately 3.74% of the share capital in issue of the Company immediately prior to the completion of the [**REDACTED**] and approximately [**REDACTED**]% of the share capital in issue of the Company immediately following the completion of the [**REDACTED**] (assuming the [**REDACTED**] is not exercised).

(c) Participants

Pursuant to the stock incentive agreements, the participants of the Pre-[**REDACTED**] Share Incentive Scheme (the "**Participant(s)**") shall include (i) management staff who have reached the position of general manager of a business division or above and have at least one year of service in the Company; (ii) core backbone personnel who have reached the position of director or above and have at least one year of service in the Company; and (iii) other employees who do not meet the above conditions but are considered necessary to be incentivized. A Participant ceases to be an eligible Participant if: (i) the Participant has been charged or held liable for (a) disclosure of the business secrets of the Group, (b) any material adverse effect on the reputation of the Group, or (c) direct or indirect economic losses of the Group; (ii) the Participant engages in competing business of the Group without prior written consent of the Company; (iii) other circumstances which cause a Participant to cease to be an eligible Participant as agreed in the stock incentive agreement occurs (collectively, the "**Causes**").

(d) Rights and Restrictions as Attached in the Award

Pursuant to the terms of the Pre-[**REDACTED**] Share Incentive Scheme, unless otherwise agreed in the Pre-[**REDACTED**] Share Incentive Scheme or decided by the Board, the selected Participants may not dispose of, transfer, pledge or otherwise encumber his or her interest in the limited partnership. Upon the [**REDACTED**] of the Company and the expiration of the lock-up period of the Shares, the Participants are entitled to apply to transfer all or partial of the Awards under the organization of the General Partner in accordance with the Pre-[**REDACTED**] Share Incentive Scheme.

(e) Lapse of the Award

The Participants may be required to withdraw from the Pre-[**REDACTED**] Share Incentive Scheme and transfer all of the interests in the Pre-[**REDACTED**] Share Incentive Scheme held by them to the General Partner in accordance with the Pre-[**REDACTED**] Share Incentive Scheme, including but not limited to (1) expiration or termination of the employment; (2) failure to meet the condition(s) as agreed in the stock incentive agreement, and/or (3) ceasing to be an eligible Participant for any Cause.

(f) Details of the Awards Granted

As of the Latest Practicable Date, details of the awards granted under the Pre-[**REDACTED**] Share Incentive Scheme are set out as below (assuming the Share Subdivision is completed).

			Approximate percentage of shareholding immediately following the completion of the [REDACTED]	
Name of grantees	**Position held in our Group**	**Number of incentive shares held**	**Assuming the [REDACTED] is not exercised**	**Assuming the [REDACTED] is exercised in full**
Connected Persons and Senior Management				
Mr. Xue Yuan (薛源)	our executive Director, chief technology officer and one of our Controlling Shareholders	7,824,525	[**REDACTED**]%	[**REDACTED**]%
Mr. Geng Lei (耿磊)	assistant to the general manager of our Company and son of Mr. Geng Fuchang	6,526,319	[**REDACTED**]%	[**REDACTED**]%
Mr. Su Yazhou (蘇亞洲)	our executive Director and chief executive officer	594,122	[**REDACTED**]%	[**REDACTED**]%
Mr. Yang Ning (楊寧)	our chief financial officer, secretary of the Board and company secretary	297,061	[**REDACTED**]%	[**REDACTED**]%
Ms. Lei Liya (雷莉婭)	supervisor of Sichuan XJND	148,531	[**REDACTED**]%	[**REDACTED**]%
Others				
Independent Third Parties	46 employees of the Group	4,809,442	[**REDACTED**]%	[**REDACTED**]%
Total	–	20,200,000	[**REDACTED**]%	[**REDACTED**]%

Disclaimers

(a) Save as disclosed in the section headed "History, Development and Corporate Structure" none of the Directors nor any of the experts referred to in "— Other Information — Qualifications and Consents of Experts" below has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by, or leased to, any member of the Group, or are proposed to be acquired or disposed of by, or leased to, any member of the Group.

(b) Save in connection with the [**REDACTED**] Agreements, none of the Directors nor any of the experts referred to in "— Other Information — Qualifications and Consents of Experts" below, is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of the Group.

(c) No cash, securities or other benefit has been paid, allotted or given within the two years preceding the date of this document to any promoter of the Company nor is any such cash securities or benefit intended to be paid, allotted or given on the basis of the [**REDACTED**] or related transactions as mentioned.

OTHER INFORMATION

Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Group.

Litigation

Save as disclosed in this document, to the knowledge of our Directors, there was no other litigation, arbitration or administrative proceeding pending or threatened against us or any of our Directors that could cause a material and adverse effect on our business, financial conditions or results of operations during the Track Record Period and up to the Latest Practicable Date.

The Sole Sponsor

The Sole Sponsor has made an application on our behalf to the [**REDACTED**] for the [**REDACTED**] of, and permission to [**REDACTED**], our Shares in issue, our Shares to be issued pursuant to the [**REDACTED**].

The Sole Sponsor satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules.

Pursuant to the engagement letter entered into between the Company and the Sole Sponsor, we have agreed to pay the Sole Sponsor a fee of US$500,000 to act as the sponsors of our Company in connection with the proposed [**REDACTED**] on the Hong Kong Stock Exchange.

Qualifications and Consents of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

Name	Qualification
Haitong International Capital Limited	A licensed corporation to conduct Type 6 (advising on corporate finance) of the regulated activities under the SFO

Name	Qualification
Ernst & Young	Certified Public Accountants and Registered Public Interest Entity Auditor
Commerce & Finance Law Offices	Legal advisor as to PRC laws
China Insights Industry Consultancy Limited	Industry consultant

As of the Latest Practicable Date, none of the experts named above has any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

BINDING EFFECT

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

BILINGUAL DOCUMENT

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

PROMOTERS

The promoters of our Company comprised all of the seven then shareholders of our Company as of July 18, 2025 before our conversion into a joint stock limited liability company.

No.	Name
1	Sichuan JND
2	Cloud Health HK
3	OAP IV
4	Hengqin National Medical Investment
5	Hengqin Cloud Healthcare
6	Chengdu Jiayue
7	Shanghai Kangrang

Within the two years immediately preceding the date of this document, no cash, securities or benefit has been paid, allotted or given, or is proposed to be paid, allotted or given to the promoters named above in connection with the [**REDACTED**] or the related transactions described in this document.

PRELIMINARY EXPENSES

The Company did not incur material preliminary expenses for the purpose of the Listing Rules.

MISCELLANEOUS

(a) Save as disclosed in "Changes in Share Capital" above, within the two years immediately preceding the date of this document:

(i) no share or loan capital or debenture of our Company or any of our subsidiaries has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid other than in cash or otherwise;

(ii) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option; and

(iii) no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries.

(b) there are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries.

(c) no share or loan capital or debenture of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option.

(d) no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of its subsidiaries by our Company for subscribing or agreeing to subscribe, or procuring or agreeing to procure subscriptions, for any shares in or debentures of our Company or any of our subsidiaries.

(e) Save as disclosed in the paragraph headed "Further Information about our Business — Summary of Material Contracts" in this section, none of our Directors or proposed Directors or experts (as named in this document), have any interest, direct or indirect, in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to, any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group. Save as disclosed in this document, no equity or debt securities of any company within our Group is presently listed on any stock exchange or traded on any trading system nor is any listing or permission to deal being or proposed to be sought.

(f) Our Company has no outstanding convertible debt securities or debentures.

(g) There is no arrangement under which future dividends are waived or agreed to be waived.

(h) There has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document.